Jiangsu Kanion Stock Hits Day Low of CNY 12.04 Amid Price Pressure

Jiangsu Kanion Pharmaceutical Co., Ltd. has experienced a notable decline today, with the stock dropping by 5.93% and reaching an intraday low of CNY 12.04. This performance reflects a broader trend of underperformance, as the company has consistently lagged behind the China Shanghai Composite index over various time frames. In the past week, Jiangsu Kanion's stock has decreased by 6.8%, while its one-month performance shows a decline of 5.41%. Over the past year, the stock has faced a significant drop of 35.71%, contrasting sharply with the 3.56% gain of the China Shanghai Composite. Year-to-date, the stock is down 14.53%, further highlighting its struggles in the market. Financial metrics indicate challenges for Jiangsu Kanion, with net sales declining at an annual rate of 1.96% and operating profit decreasing by 16.74% over the last five years. The company has reported negative results for the last two consecutive quarters, contributing to its ongoing underperformance. With a market capitalization of CNY 7,373 million, Jiangsu Kanion continues to navigate a challenging landscape in the pharmaceuticals and biotechnology sector.